Biotech | May 27, 2022
Lancet publishes results of Phase 3 programmes of Rinvoq in Ulcerative Colitis
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
The study was conducted in equal laboratory conditions in the Spallanzani Institute in Italy on comparable sera samples from individuals vaccinated with Sputnik V and Pfizer with a similar level of IgG antibodies and virus-neutralizing activity (VNA) against Wuhan variant.
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Approval follows CHMP recommendation for use in patients previously vaccinated with Vaxzevria or an EU-approved mRNA Covid-19 vaccine
The two companies will work together for the Prospective Evaluation of OrionAI – a revolutionary AI-based Diagnostic Assistant for Histological Examination of a variety of solid tumours beginning with Head and Neck Squamous Cell Carcinoma (HNSCC) Cancer
The European Commission granted CMA in December 2021 for use of Nuvaxovid in individuals aged 18 and over, and Novavax filed for expanded CMA for use in adolescents aged 12 through 17 in March 2022
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
Subscribe To Our Newsletter & Stay Updated
